Skip to main content
HOUSE 2751117th CongressReferred to the Subcommittee on the Constitution, Civil Rights, and Civil Liberties.

PFAS Accountability Act of 2021

Last Action
10/19/2021

Actions

  • 2021-10-19Referred to the Subcommittee on the Constitution, Civil Rights, and Civil Liberties.
  • 2021-04-23Referred to the Subcommittee on Environment and Climate Change.
  • 2021-04-22Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2021-04-22Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • 2021-04-22Introduced in House
  • 2021-04-22Introduced in House

CRS Summary

As of 2021-04-22 (00)

PFAS Accountability Act of 2021

This bill provides a cause of action under the Toxic Substances Control Act for individuals or classes of individuals who were significantly exposed to perfluoroalkyl or polyfluoroalkyl substances, commonly referred to as PFAS. These substances are man-made and may have adverse human health effects. A variety of products contain the compounds, such as nonstick cookware or weatherproof clothing.

Specifically, the bill provides a cause of action those who were significantly exposed to PFAS (or have reasonable grounds to believe they were exposed) against persons who engaged in any portion of a manufacturing process that created the PFAS and foresaw (or reasonably should have foreseen) the creation or use of PFAS would result in human exposure.

The bill authorizes a court to award medical monitoring to claimants if (1) they have been significantly exposed to PFAS, (2) they have an increased risk of developing a disease associated with such exposure, (3) the increased risk provides a reasonable basis to conclude that periodic diagnostic medical examinations is necessary, and (4) the medical examinations are effective in detecting a disease associated with PFAS exposure.

The bill establishes a presumption of significant exposure to PFAS if the claimant (1) provides medical results proving the presence of PFAS in the body, or (2) demonstrates the defendant's manufacturing process created the PFAS to which the claimant was exposed and the PFAS were released into one or more areas where the claimant would have been exposed for at least one year.

Cosponsors (9)

  • Daniel Kildee (D-MI)
  • Rashida Tlaib (D-MI)
  • JERROLD NADLER (D-NY)
  • Brendan Boyle (D-PA)
  • Marilyn Strickland (D-WA)
  • Debbie Dingell (D-MI)
  • Marie Newman (D-IL)
  • Sean Maloney (D-NY)
  • Mondaire Jones (D-NY)

Subjects

  • Blood and blood diseases
  • Civil actions and liability
  • Environmental assessment, monitoring, research
  • Environmental health
  • Federal district courts
  • Hazardous wastes and toxic substances
  • Health care costs and insurance
  • Health care coverage and access
  • Health promotion and preventive care
  • Manufacturing
  • Medical research
  • Medical tests and diagnostic methods
  • Pollution liability
Read on Congress.gov

Sourced from Congress.gov (public domain).

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.